At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Nasal Glucagon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Site, Randomized, Four-Way, Four-Period PK/PD Crossover Phase 1 Clinical Study in 16 Fasted Healthy Adult Volunteers Receiving 3 Dose Levels of Intranasally Administered Glucagon and One Dose Level of Glucagon Administered by Subcutaneous Injection
In Brief
A Phase 1 clinical trial evaluating Nasal Glucagon and Glucagon for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The main purpose of this study was to evaluate the safety and tolerability of nasal glucagon (NG). The study drug was delivered into the participant's nostril (intranasally) or was given as an injection just under the skin (subcutaneously) once in each of four study periods. The study lasted about 23 days for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
CollaboratorsLocemia Solutions ULC
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
Primary CompletionOct 2011
Study CompletionNov 2011
First PostedMay 2016
TodayJul 2026
First PostedMay 19, 2016
Enrollment StartOct 1, 2011
Primary CompletionOct 1, 2011
Study CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 10.1 years ago
Interventions
Nasal Glucagondrug
Administered intranasally.
Glucagondrug
Administered SC.